Skip to content

Indian Market Shaken by US Generic Drug Tariff Proposal

By News Analysis India · · 1 min read

On July 22, pharmaceutical shares on the Mumbai exchange tumbled after the announcement of a sweeping tariff scheme by the United States. President Donald Trump posted that from August 2026 the U.S. will allow a duty‑free window for generic drug imports for two years, after which a 100 percent tariff will be levied for one year and subsequently raised to 200 percent.

The NSE’s Nifty Pharma index dropped more than two percent, dragging down the broader market. By mid‑morning, Gland Pharma fell 4.62 percent, Piramal Pharma 3.92 percent, Lupin 3.81 percent, J B Chemicals 3.87 percent, Ajanta Pharma 3.03 percent, Cipla 1.87 percent, Menkind Pharma 1.69 percent, Dr. Reddys Labs 1.49 percent, Sun Pharma 1.00 percent and Biocon 1.01 percent.

Trump’s rationale centers on reviving domestic manufacturing of generic medicines. He warned that firms that do not set up production plants and equipment in the United States within the deadline will be penalised with the elevated duties. Existing rules for patented, branded and innovative drugs will stay the same.

The domestic market mirrored the sentiment, with the Sensex slipping 658 points, or 0.85 percent, to 76,811, while the Nifty fell 182 points, or 0.77 percent, to 24,002.